Review
doi: 10.1016/j.coph.2004.06.001.
New nucleoside reverse transcriptase inhibitors for the treatment of HIV infections
Affiliations
- PMID: 15351346
- DOI: 10.1016/j.coph.2004.06.001
Item in Clipboard
Review
New nucleoside reverse transcriptase inhibitors for the treatment of HIV infections
Curr Opin Pharmacol.
2004 Oct.
Abstract
Several new nucleoside analogs are currently in development for the treatment of HIV-1 infections. Alovudine, amdoxovir, elvucitabine, Racivir, Reverset and SPD 754 are nucleoside reverse transcriptase inhibitors that were designed and selected in anticipation of having improved resistance, safety, compatibility and efficacy profiles. Clinical trials are demonstrating that some of these goals are being met, and that nucleoside analogs as a class of compounds remain fertile ground for finding valuable additions to current anti-retrovirus treatment regimens.
Similar articles
-
Biochemical and mechanistic basis for the activity of nucleoside analogue inhibitors of HIV reverse transcriptase.Curr Top Med Chem. 2004;4(10):1035-44. doi: 10.2174/1568026043388358. Curr Top Med Chem. 2004. PMID: 15193137 Review.
-
[Nucleoside analogs inhibiting reverse transcriptase: use in adult patient with HIV infection].Enferm Infecc Microbiol Clin. 1996 Oct;14 Suppl 1:3-9. Enferm Infecc Microbiol Clin. 1996. PMID: 9053024 Review. Spanish. No abstract available.
-
[Current situation of nucleoside reverse transcriptase inhibitors].Ann Med Interne (Paris). 2000 Jun;151(4):255-9. Ann Med Interne (Paris). 2000. PMID: 10922952 Review. French.
-
[Improved long-term success. New nucleoside for once daily combinations].MMW Fortschr Med. 2004 Apr 26;146 Spec No 1:31-3. MMW Fortschr Med. 2004. PMID: 15373043 German. No abstract available.
-
New drugs.HIV Med. 2005 Jul;6(4):225-31. doi: 10.1111/j.1468-1293.2005.00310.x. HIV Med. 2005. PMID: 16011526 Review. No abstract available.
Cited by
-
Design and profiling of GS-9148, a novel nucleotide analog active against nucleoside-resistant variants of human immunodeficiency virus type 1, and its orally bioavailable phosphonoamidate prodrug, GS-9131.Antimicrob Agents Chemother. 2008 Feb;52(2):655-65. doi: 10.1128/AAC.01215-07. Epub 2007 Dec 3. Antimicrob Agents Chemother. 2008. PMID: 18056282 Free PMC article.
-
Synthesis and Biological Evaluation of 5'-O-Dicarboxylic Fatty Acyl Monoester Derivatives of Anti-HIV Nucleoside Reverse Transcriptase Inhibitors.Tetrahedron Lett. 2014 Mar 19;55(12):1983-1986. doi: 10.1016/j.tetlet.2014.02.001. Tetrahedron Lett. 2014. PMID: 24791029 Free PMC article.
-
Multiple-dose pharmacokinetic behavior of elvucitabine, a nucleoside reverse transcriptase inhibitor, administered over 21 days with lopinavir-ritonavir in human immunodeficiency virus type 1-infected subjects.Antimicrob Agents Chemother. 2009 Feb;53(2):662-9. doi: 10.1128/AAC.00907-08. Epub 2008 Nov 17. Antimicrob Agents Chemother. 2009. PMID: 19015343 Free PMC article.
-
Synthesis of Spironucleosides: Past and Future Perspectives.Molecules. 2017 Nov 22;22(11):2028. doi: 10.3390/molecules22112028. Molecules. 2017. PMID: 29165398 Free PMC article. Review.
-
Antiretroviral drugs: critical issues and recent advances.Indian J Pharmacol. 2012 May;44(3):288-98. doi: 10.4103/0253-7613.96296. Indian J Pharmacol. 2012. PMID: 22701234 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Miscellaneous
